Form 4 for EBS Emergent BioSolutions Inc.
Accepted 2026-03-05 00:00:00 ET · period of report 2026-03-03 · accession 0001919170-26-000009 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-05 | 2026-03-05 | EBS | Glessner Coleen | EVP, Quality, Ethics, CPL | F - Tax | $8.44 | -8,199 | 104.1K | -7% | -$69.2K |
| D | 2026-03-05 | 2026-03-03 | EBS | Glessner Coleen | EVP, Quality, Ethics, CPL | A - Grant | $0.00 | +44.8K | 294.4K | +18% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-05 | F | D | 8,199 | $8.44 | 104,108 | D | — | — | (F1) Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units |
| 2 | Derivative | Employee Stock Option (Right to buy) | 2026-03-03 | A | A | 44,834 | $0.00 | 294,447 | D | $8.99 · — to 2033-03-02 | 44,834 Common Stock | (F2) Vests in three equal installments beginning on the day prior to the anniversary date of the grant. |